This is a 2-part, open-label, drug-drug interaction (DDI) study to assess the effect of phenytoin (a strong CYP3A4 inducer) and itraconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics of pelabresib in healthy participants.
The study includes two parts, each with two treatment periods. In Part 1, participants will be administered pelabresib in Treatment Period 1 and pelabresib and phenytoin in Treatment Period 2.
In Part 2, participants will be administered pelabresib in Treatment Period 1 and pelabresib and itraconazole in Treatment Period 2.
How understandable was the trial content above?
Hard to understand
Easy to understand
